Claims
- 1. An isolated lymphotoxin having the following amino acid sequence (I): ##STR32##
- 2. An isolated lymphotoxin having the following amino acid sequence (II):
- ______________________________________MET HIS LEU ALA HIS SER ASN LEU LYS PROALA ALA HIS LEU ILE GLY ASP PRO SER LYSGLN ASN SEN LEU LEU TRP ARG ALA ASN THRASP ARG ALA PHE LEU GLN ASP GLY PHE SERLEU SER ASN ASN SER LEU LEU VAL PRO THRSER GLY ILE TYR PHE VAL TYR SER GLN VALVAL PHE SER GLY LYS ALA TYR SER PRO LYSALA THR SER SER PRO LEU TYR LEU ALA HISGLU VAL GLN LEU PHE SER SER GLN TYR PROPHE HIS VAL PRO LEU LEU SER SER GLN LYSMET VAL TYR PRO GLY LEU GLN GLU PRO TRPLEU HIS SER MET TYR HIS GLY ALA ALA PHEGLN LEU THR GLN GLY ASP GLN LEU SER THRHIS THR ASP GLY ILE PRO HIS LEU VAL LEUSER PRO SER THR VAL PHE PHE GLY ALA PHEALA LEU.______________________________________
- 3. An isolated lymphotoxin having the following amino acid sequence (III):
- ______________________________________1 10MET HIS LEU ALA SER ASN LEU LYS PRO ALA 20ALA HIS LEU ILE GLY ASP PRO SER LYS GLN 30ASN SER LEU LEU TRP ARG ALA ASN THR ASP 40ARG ALA PHE LEU GLN ASP GLY PHE SER LEU 50SER ASN ASN SER LEU LEU VAL PRO THR SER 60GLY ILE TYR PHE VAL TYR SER GLN VAL VAL 70PHE SER GLY LYS ALA TYR SER PRO LYS ALA 80THR SER SER PRO LEU TYR LEU ALA HIS GLU 90VAL GLN LEU PHE SER SER GLN TYR PRO PHE 100HIS VAL PRO LEU LEU SER SER GLN LYS MET 110VAL THR PRO GLY LEU GLN GLU PRO TRP LEU 120HIS SER MET TYR HIS GLY ALA ALA PHE GLN 130LEU TYR GLN GLY ASP GLN LEU SER THR HIS 140THR ASP GLY ILE PRO HIS LEU VAL LEU SER 150PRO SER THR VAL PHE PHE GLY ALA PHE ALALEU.______________________________________
- 4. An antitumor composition which comprises, as an active ingredient, a tumor treating effective amount of a lymphotoxin having the following amino acid sequence (I):
- ______________________________________MET ASP PRO ALA GLN THR ALA ARG GLN HISPRO LYS MET HIS LEU ALA HIS SER ASN LEULYS PRO ALA ALA HIS LEU ILE GLY ASP PROSER LYS GLN ASN SER LEU LEU TRP ARG ALAASN THR ASP ARG ALA PHE LEU GLN ASP GLYPHE SER LEU SER ASN ASN SER LEU LEU VALPRO THR SER GLY ILE TYR PHE VAL THR SERGLN VAL VAL PHE SER GLY LYS ALA TYR SERPRO LYS ALA THR SER SER PRO LEU TYR LEUALA HIS GLU VAL GLN LEU PHE SER SER GLNTYR PRO PHE HIS VAL PRO LEU LEU SER SERGLN LYS MET VAL TYR PRO GLY LEU GLN GLUPRO TRP LEU HIS SER MET TYR HIS GLY ALAALA PHE GLN LEU THR GLN GLY ASP GLN LEUSER THR HIS THR ASP GLY ILE PRO HIS LEUVAL LEU SER PRO SER THR VAL PHE PHE GLYALA PHE ALA LEU______________________________________
- and a pharmaceutically acceptable carrier.
- 5. An antitumor composition which comprises, as an active ingredient, a tumor treating effective amount of a lymphotoxin having the following amino acid sequence (II):
- ______________________________________MET HIS LEU ALA HIS SER ASN LEU LYS PROALA ALA HIS LEU ILE GLY ASP PRO SER LYSGLN ASN SER LEU LEU TRP ARG ALA ASN THRASP ARG ALA PHE LEU GLN ASP GLY PHE SERLEU SER ASN ASN SER LEU LEU VAL PRO THRSER GLY ILE TYR PHE VAL TYR SER GLN VALVAL PHE SER GLY LYS ALA TYR SER PRO LYSALA THR SER SER PRO LEU TYR LEU ALA HISGLU VAL GLN LEU PHE SER SER GLN TYR PROPHE HIS VAL PRO LEU LEU SER SER GLN LYSMET VAL TYR PRO GLY LEU GLN GLU PRO TRPLEU HIS SER MET TYR HIS GLY ALA ALA PHEGLN LEU THR GLN GLY ASP GLN LEU SER THRHIS THR ASP GLY ILE PRO HIS LEU VAL LEUSER PRO SER THR VAL PHE PHE GLY ALA PHEALA LEU______________________________________
- and a pharmaceutically acceptable carrier.
- 6. An antitumor composition which comprises, as an active ingredient, a tumor treating effective amount of a lymphotoxin having the following amino acid sequence (III):
- ______________________________________1 10MET HIS LEU ALA SER ASN LEU LYS PRO ALA 20ALA HIS LEU ILE GLY ASP PRO SER LYS GLN 30ASN SER LEU LEU TRP ARG ALA ASN THR ASP 40ARG ALA PHE LEU GLN ASP GLY PHE SER LEU 50SER ASN ASN SER LEU LEU VAL PRO THR SER 60GLY ILE TYR PHE VAL TYR SER GLN VAL VAL 70PHE SER GLY LYS ALA TYR SER PRO LYS ALA 80THR SER SER PRO LEU TYR LEU ALA HIS GLU 90VAL GLN LEU PHE SER SER GLN TYR PRO PHE 100HIS VAL PRO LEU LEU SER SER GLN LYS MET 110VAL THR PRO GLY LEU GLN GLU PRO TRP LEU 120HIS SER MET TYR HIS GLY ALA ALA PHE GLN 130LEU THR GLN GLY ASP GLN LEU SER TYR HIS 140THR ASP GLY ILE PRO HIS LEU VAL LEU SER 150PRO SER THR VAL PHE PHE GLY ALA PHE ALALEU______________________________________
- and a pharmaceutically acceptable carrier.
Priority Claims (4)
Number |
Date |
Country |
Kind |
60-289249 |
Dec 1985 |
JPX |
|
61-151772 |
Jun 1986 |
JPX |
|
61-151773 |
Jun 1986 |
JPX |
|
62-160115 |
Jun 1987 |
JPX |
|
CROSS REFERENCE TO RELATED APPLICATIONS
This is a divisional of U.S. patent application Ser. No. 07/733,974, filed 22 Jul. 1991, now U.S. Pat. No. 5,403,725, which is a continuation of U.S. patent application Ser. No. 07/212,293, filed 27 Jun. 1988, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 06/945,904, filed 23 Dec. 1986, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4920196 |
Aggarwal |
Apr 1990 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
733974 |
Jul 1991 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
212293 |
Jun 1988 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
945904 |
Dec 1986 |
|